The role of pharmacotherapy in the treatment of mental disorders in patients who have undergone COVID-19 and have been exposed to SARS-CoV-2 pandemic stressors

The COVID-19 pandemic has multifaceted influenced to mental health and the development of psychopathological symptoms. The article presents the approaches to the treatment of psychopathological states in persons who have undergone COVID-19 and have been exposed to the SARS-CoV-2 pandemic stressors. The structure of psychopathological disorders included endogenous affective disorders, namely depressive episodes, recurrent depressive disorders (F32, F33), neurotic, associated with stress and somatoform disorders (F4) and psychopathological conditions of the organic genesis (F06). The clinical condition of patients in the dynamics of therapy was evaluated by the clinical and psychopathological method, psychopathological disorders are evaluated using a psychometric method. Treatment has been developed on the basis of certain targets of therapeutic influence for the specified category of patients: clinical-anamnestic, clinical-psychopathological and psychological and were specific to different groups of diseases. The most significant clinical features are the psychopathological disorders of the predominantly affective and alarming spectrum, which were accompanied by significant somato-vegetative symptoms and cognitive changes. The role of pharmacotherapy, developed on the basis of certain clinical manifestations and its relationship with psychotherapy in complex treatment, depending on the peculiarities of psychopathology, was determined. In depressive disorders, it can be leading at the beginning and supporting at later stages (psychotherapy comes to the fore); in neurotic, stress-related and somatoform, psychotherapy should be leading, and pharmacotherapy should be auxiliary; in mental disorders of organic origin, pharmacotherapy and psychotherapy are equally important. Keywords: mental disorders therapy, targeting therapy, evaluation of therapy.